Pharmaceutical companies have been through a massive transition period that has lead to a new marketplace with more challenges in terms of innovation, diversification and pressures on efficiency and affordability.
As a result of this transition, pharmaceutical companies are facing new issues such as:
- A need for real differentiation in the R&D pipeline coming from both a regulatory and buying perspective.
- A need to remodel market access. With all the change in regulation, direct sales forces are no longer as effective as they used to be and the channels to market have changed dramatically. The increasing importance of emerging markets is also forcing pharmaceutical companies to realign their global footprint.
- Pressure on costs resulting from a more competitive market: manufacturing and supply chains have now suddenly received more attention than they did previously.
